BioCentury
ARTICLE | Preclinical News

CARB-X reveals first investments

March 30, 2017 10:50 PM UTC

Public-private partnership Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) said it is investing $24 million in 11 early stage biotechs developing new antibiotic classes, nontraditional antimicrobial approaches, and other therapeutics and diagnostics to treat Gram-negative bacteria. The investments are CARB-X's first.

CARB-X said it would invest up to $24 million more in the companies based on milestones over the next three years. The companies themselves are expected to invest more than $25 million in the projects CARB-X funds...